News

Deal Announcements

Carbylan Therapeutics Nets Venture Capital Debt

Monday, March 9, 2015 5:33:00 AM PDT | VentureDeal
   Palo Alto, California  --  Pharmaceutical developer Carbylan Therapeutics has secured $4 million in new venture capital debt financing, according to an SEC regulatory filing.

Carbylan is developing a rapid and sustained pain relief drug, Hydros-TA.

The drug promises to provide pain reduction via a single intra-articular injection.

Investors in the financing were not disclosed, nor was how the company intends to use the debt proceeds.

Carbylan is backed by investors such as Alta Partners, InterWest Partners and Vivo Ventures.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1